Radiation therapy for intrahepatic malignancies

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1511-1521

  Quick, Allison M ^a   Lo, Simon S ^a   Mayr, Nina A ^a   Kim, Edward Y ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Intrahepatic; Malignancies; Radiation therapy

Indexed keywords

HOLMIUM; IODINATED POPPYSEED OIL; IODINE 131; YTTRIUM 90;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; PROTON THERAPY; RADIATION DOSE; RADIATION RESPONSE; REVIEW;

CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 70350605530     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.114     Document Type: Review

References (73)

1. American Cancer Society. Colorectal Cancer Facts & Figures 2008-2010. American Cancer Society, Atlanta, USA (2008).
2. Dawson LA, McGinn CJ, Lawrence TS. Conformal chemoradiation for primary and metastatic liver malignancies. Semin. Surg. Oncol. 21(4), 249-255 (2003).
3. Gates VL, Atassi B, Lewandowski RJ et al. Radioembolization with Yttrium 90 microspheres: review of an emerging treatment for liver tumors. Future Oncol. 3(1), 73-81 (2007). (Pubitemid 46268018)
4. Ben-Josef E, Lawrence TS. Radiotherapy for unresectable hepatic malignancies. Semin. Radiat. Oncol. 15(4), 273-278 (2005).
5. Salem R, Hunter RD. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma: a review. Int. J. Radiat. Oncol. Biol. Phys. 66(2 Suppl. 1), S83 (2006). (Pubitemid 44353960)
6. Park W, Lim DH, Paik SW et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 61(4), 1143-1150 (2005). (Pubitemid 40340909)
7. Allgaier HP, Deibert P, Olschewski M et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int. J. Cancer 79(6), 601-605 (1998). (Pubitemid 28549471)
8. Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br. J. Surg. 89(11), 1396-1401 (2002).
9. Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst. Rev. 2, CD003046 (2004).
10. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann. Surg. 232(3), 381-391 (2000). (Pubitemid 30677826)
11. Sutherland LM, Williams JAR, Padbury RTA et al. Radiofrequency ablation of liver tumors: a systematic review. Arch. Surg. 141(2), 181-190 (2006).
12. Lau WY, Lai ECH. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann. Surg. 249(1), 20-25 (2009).
13. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164-1171 (2002). (Pubitemid 34454013)
14. Ben-Josef E, Normolle D, Ensminger WD et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 23(34), 8739-8747 (2005). (Pubitemid 46211519)
15. Liang S-X, Zhu X-D, Xu Z-Y et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int. J. Radiat. Oncol. Biol. Phys. 65(2), 426-434 (2006).
16. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106(8), 1653-1663 (2006).
17. Fuss M, Salter BJ, Herman TS, Thomas JCR. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology 127(5 Suppl. 1), S206 (2004). (Pubitemid 39423389)
18. Krishnan S, Dawson LA, Seong J et al. Radiotherapy for hepatocellular carcinoma: an overview. Ann. Surg. Oncol. 15(4), 1015-1024 (2008).
19. Kim JH, Park J-W, Kim TH et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 69(3), 813-819 (2007).
20. Dawson LA, McGinn CJ, Normolle D et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 18(11), 2210-2218 (2000). •• Phase I trial reporting improved survival of patients with unresectable hepatic malignancies over historical controls after receiving high-dose focal radiation using 3D conformal radiation therapy (CRT) with concurrent hepatic artery fluorodeoxyuridine. (Pubitemid 30350212)
21. Dawson LA, Normolle D, Balter JM et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int. J. Radiat. Oncol. Biol. Phys. 53(4), 810-821 (2002). (Pubitemid 34722625)
22. Lawrence TS, Ten Haken RK, Kessler ML et al. The use of 3D dose volume analysis to predict radiation hepatitis. Int. J. Radiat. Oncol. Biol. Phys. 23(4), 781-788 (1992). • Demonstrated the use of mean liver dose and correlation with the normal tissue complication probability model to determine the risk of radiation-induced liver disease following focal radiation using 3DCRT.
23. Mornex F, Girard N, Beziat C et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial. Int. J. Radiat. Oncol. Biol. Phys. 66(4), 1152-1158 (2006). (Pubitemid 44740208)
24. Robertson JM, Lawrence TS, Walker S et al. The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 32(2), 445-450 (1995).
25. Thomas E, Chapet O, Kessler ML, Lawrence TS, Ten Haken RK. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors. Int. J. Radiat. Oncol. Biol. Phys. 62(2), 571-578 (2005). (Pubitemid 40704477)
26. Eccles CL, Bissonnette JP, Craig T et al. Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 72(2), 582-588 (2008).
27. Milano MT, Chmura SJ, Garofalo MC et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int. J. Radiat. Oncol. Biol. Phys. 59(2), 445 (2004).
28. Cheng JC, Wu J-K, Huang C-M et al. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int. J. Radiat. Oncol. Biol. Phys. 56(1), 229-234 (2003).
29. Gray BN, Anderson JE, Burton MA et al. Regression of liver metastases following treatment with yttrium 90 microspheres. Aust. NZ J. Surg. 62(2), 105-110 (1992).
30. Dawson LA, Eccles C, Bissonnette JP, Brock KK. Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int. J. Radiat. Oncol. Biol. Phys. 62(4), 1247-1252 (2005). (Pubitemid 40884441)
31. Wagman R, Yorke E, Ford E et al. Respiratory gating for liver tumors: use in dose escalation. Int. J. Radiat. Oncol. Biol. Phys. 55(3), 659-668 (2003). (Pubitemid 36170007)
32. Shirato H, Shimizu S, Kitamura K, Onimaru R. Organ motion in image-guided radiotherapy: lessons from real-time tumor-tracking radiotherapy. Int. J. Clin. Oncol. 12(1), 8-16 (2007). (Pubitemid 46472559)
33. Fuss M, Salter BJ, Cavanaugh SX et al. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1245-1256 (2004). (Pubitemid 38834321)
34. Hawkins MA, Brock KK, Eccles C Moseley D, Jaffray D, Dawson LA. Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 610-619 (2006). (Pubitemid 44332721)
35. Herfarth KK, Debus J, Lohr F et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int. J. Radiat. Oncol. Biol. Phys. 46(2), 329-335 (2000). (Pubitemid 30067782)
36. Mendez Romero A, Wunderink W, Hussain SM et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution Phase I-II study. Acta Oncol. 45(7), 831-837 (2006). (Pubitemid 44423129)
37. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 45(7), 856-864 (2006). (Pubitemid 44423132)
38. Herfarth KK, Debus J, Lohr F et al. Stereotactic single-dose radiation therapy of liver tumors: results of a Phase I/II trial. J. Clin. Oncol. 19(1), 164-170 (2001). (Pubitemid 32063493)
39. Fuss M, Thomas CR Jr. Stereotactic body radiation therapy: an ablative treatment option for primary and secondary liver tumors. Ann. Surg. Oncol. 11(2), 130-138 (2004). (Pubitemid 40486787)
40. Tse RV, Hawkins M, Lockwood G et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 26(4), 657-664 (2008). • Phase I trial showing safety and feasibility of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma. (Pubitemid 351264363)
41. Lee MT, Kim JJ, Dinniwell R et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J. Clin. Oncol. 27(10), 1585-1591 (2009). • Phase I trial showing safety and feasibility of SBRT for liver metastases.
42. Olsen CC, Welsh J, Kavanagh BD et al. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 73(5), 1414-1424 (2009).
43. Hata M, Tokuuye K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 104(4), 794-801 (2005). (Pubitemid 40685599)
44. Hata M, Tokuuye K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther. Onkol. 182(12), 713-720 (2006). (Pubitemid 44887173)
45. Hata M, Tokuuye K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 107(3), 591-598 (2006). (Pubitemid 44107220)
46. Sugahara S, Oshiro Y, Nakayama H et al. Proton beam therapy for large hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2009.02.030 (2009) (Epub ahead of print).
47. Hata M, Tokuuye K, Sugahara S et al. Proton beam therapy for aged patients with hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 69(3), 805-812 (2007). (Pubitemid 47418403)
48. Chiba T, Tokuuye K, Matsuzaki Y et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin. Cancer Res. 11(10), 3799-3805 (2005). (Pubitemid 40685599)
49. Fukumitsu N, Sugahara S, Nakayama H et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 74(3), 831-836 (2009).
50. Mizumoto M, Tokuuye K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 462-467 (2008). • Prospective study demonstrating the local control rates and safety of proton-beam therapy for patients with HCC located away from the porta hepatis or GI tract.
51. Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a Phase II trial. Gastroenterology, 127(5 Suppl. 1), S189-S193 (2004).
52. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47(1), 71-81 (2008).
53. Murthy R, Nunez R, Szklaruk J et al. Yttrium 90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl. 1), S41-S55 (2005). (Pubitemid 41686061)
54. 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur. J. Nucl. Med. Mol. Imaging 35(11), 2088-2096 (2008).
55. Kulik LM, Atassi B, van Holsbeeck L et al. Yttrium 90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J. Surg. Oncol. 94(7), 572-586 (2006). (Pubitemid 44851918)
56. Geschwind JFH, Salem R, Carr BI et al. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S194-S205 (2004). (Pubitemid 39423388)
57. 90Y-microspheres. J. Nucl. Med. 41(10), 1673-1681 (2000).
58. Mulcahy MF, Lewandowski RJ, Ibrahim SM et al. Radioembolization of colorectal hepatic metastases using yttrium 90 microspheres. Cancer 115(9), 1849-1858 (2009).
59. 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int. J. Radiat. Oncol. Biol. Phys. 65(2), 412-425 (2006).
60. Raoul JL, Boucher E, Roland V, Garin E. 131-iodine lipiodol therapy in hepatocellular carcinoma. Q. J. Nucl. Med. Mol. Imaging 53(3), 348-355 (2005).
61. Lau WY, Lai ECH, Leung TWT, Yu SCH. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann. Surg. 247(1), 43-48 (2008).
62. 131I- labelled lipiodol. Br. J. Surg. 90(11), 1379-1383 (2003).
63. 131I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J. Nucl. Med. 50(6), 871-877 (2009).
64. Sohn JH, Choi HJ, Lee JT et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology (Basel) 76(1), 1-9 (2009).
65. Vente MA, Hobbelink MG, van Het Schip AD, Zonnenberg BA, Nijsen JF. Radionuclide liver cancer therapies: from concept to current clinical status. Anticancer Agents Med. Chem. 7(4), 441-459 (2007).
66. Wulf J, Guckenberger M, Haedinger U et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 45(7), 838-847 (2006). (Pubitemid 44423130)
67. Rusthoven KE, Kavanagh BD, Cardenes H et al. Multi-institutional Phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27(10), 1572-1578 (2009). • Multi-institutional Phase I/II trial demonstrating the safety and efficacy of high-dose liver SBRT for patients with one to three hepatic metastases.
68. Jakobs TF, Hoffmann RT, Fischer T et al. Radioembolization in patients with hepatic metastases from breast cancer. J. Vasc. Interv. Radiol. 19(5), 683-690 (2008).
69. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann. Surg. 247(6), 1029-1035 (2008).
70. Park HC, Seong J, Han KH et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 54(1), 150-155 (2002). (Pubitemid 34899660)
71. Liu M-T, Li S-H, Chu T-C et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn. J. Clin. Oncol. 34(9), 532-539 (2004).
72. Lau WY, Ho S, Leung TW et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intra-arterial infusion of 90yttrium microspheres. Int. J. Radiat. Oncol. Biol. Phys. 40(3), 583-592 (1998). (Pubitemid 28104228)
73. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, USA (2008) http://seer.cancer.gov/csr/1975-2005/